Baseline patient and transplant characteristics
| . | N . | % . |
|---|---|---|
| Total | 25 | 100 |
| Age at enrollment | ||
| Median (range) | 52 (23, 68) | |
| Time from BMT to study | ||
| Median (range) in months | 37 (14, 92) | |
| Time from cGVHD onset to study | ||
| Median (range) in months | 26.6 (3.6, 83.9) | |
| No. of cGVHD sites involved | ||
| Median (range) | 3 (1, 6) | |
| No. of prior therapies including steroid | ||
| Median (range) | 4 (2, 9) | |
| Daily prednisone dose | ||
| Median (range), mg | 30 (5, 80) | |
| Prior Grade I-IV acute GVHD | 11 | 44 |
| Patient sex | ||
| Male | 19 | 76 |
| Female | 6 | 24 |
| Male patient and female donor | 9 | 36 |
| Diagnosis | ||
| AML | 8 | 32 |
| CML | 1 | 4 |
| Hodgkin’s disease | 1 | 4 |
| ALL | 3 | 12 |
| MDS | 4 | 16 |
| MPD | 1 | 4 |
| NHL | 7 | 28 |
| Conditioning intensity∗ | ||
| MAC | 12 | 50 |
| RIC | 12 | 50 |
| HLA type (A, B, C, DRB1) | ||
| Matched unrelated | 18 | 72 |
| Matched related | 5 | 20 |
| Mismatched unrelated | 2 | 8 |
| Cell source∗ | ||
| Bone marrow | 2 | 8.3 |
| PBSC | 22 | 92 |
| CMV serological status | ||
| Patient or donor positive | 8 | 32 |
| . | N . | % . |
|---|---|---|
| Total | 25 | 100 |
| Age at enrollment | ||
| Median (range) | 52 (23, 68) | |
| Time from BMT to study | ||
| Median (range) in months | 37 (14, 92) | |
| Time from cGVHD onset to study | ||
| Median (range) in months | 26.6 (3.6, 83.9) | |
| No. of cGVHD sites involved | ||
| Median (range) | 3 (1, 6) | |
| No. of prior therapies including steroid | ||
| Median (range) | 4 (2, 9) | |
| Daily prednisone dose | ||
| Median (range), mg | 30 (5, 80) | |
| Prior Grade I-IV acute GVHD | 11 | 44 |
| Patient sex | ||
| Male | 19 | 76 |
| Female | 6 | 24 |
| Male patient and female donor | 9 | 36 |
| Diagnosis | ||
| AML | 8 | 32 |
| CML | 1 | 4 |
| Hodgkin’s disease | 1 | 4 |
| ALL | 3 | 12 |
| MDS | 4 | 16 |
| MPD | 1 | 4 |
| NHL | 7 | 28 |
| Conditioning intensity∗ | ||
| MAC | 12 | 50 |
| RIC | 12 | 50 |
| HLA type (A, B, C, DRB1) | ||
| Matched unrelated | 18 | 72 |
| Matched related | 5 | 20 |
| Mismatched unrelated | 2 | 8 |
| Cell source∗ | ||
| Bone marrow | 2 | 8.3 |
| PBSC | 22 | 92 |
| CMV serological status | ||
| Patient or donor positive | 8 | 32 |
AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; MPD, myeloproliferative disease; NHL, non-Hodgkin’s lymphoma; MAC, myeloablative conditioning; RIC, reduced intensity conditioning; PBSC, peripheral blood stem cells.
Details are unknown for 1 patient who underwent transplant at another center.